Knight

As of February 2024, Knight had submitted marketing authorization applications for fostamatinib in Brazil, Colombia and Mexico.

Rigel received an upfront cash payment, with the potential for additional regulatory and commercial milestones, and stepped-up royalties based on tiered net sales. In return, Knight receives exclusive rights to fostamatinib in all potential indications in Latin America.